UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 17, 2023
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification Number)
|
(Address of principal executive offices, including zip code)
(Registrant's telephone number, including area code)
(781 ) 522-3000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
| New York Stock Exchange |
||||
| (CUSIP 75513E 101) |
||||
| 2.150% Notes due 2030 |
RTX 30 |
New York Stock Exchange |
||
| (CUSIP 75513E AB7) |
Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Refusal of Director to stand for re-election
On February 17, 2023, Margaret L. O’Sullivan informed Raytheon Technologies Corporation (the “Company”) of her intention not to seek re-election as a member
of the Board of Directors of the Company (the “Board”) at the 2023 Annual Meeting of Stockholders due to the additional demands on her time resulting from her recently announced appointment. Dr. O’Sullivan will continue as a member of the Board
until the 2023 Annual Meeting. Dr. O’Sullivan has been a distinguished member of, and has provided significant contributions and guidance to, the Board. Dr. O’Sullivan’s departure from the Board is not a result of any disagreement with the
Company. In connection with Dr. O’Sullivan’s departure, the Board will decrease its size from fourteen to thirteen directors effective upon completion of Dr. O’Sullivan’s term as a director.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 104 |
Cover Page Interactive Data File – the cover page XBRL tags are embedded within the
Inline XBRL document.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| RAYTHEON TECHNOLOGIES CORPORATION |
|||
|
Date: February 21, 2023
|
By:
|
/s/ Ramsaran Maharajh |
|
| Ramsaran Maharajh |
|||
| Executive Vice President & General Counsel |
|||